Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Fineline Cube Aug 5, 2026
Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Fineline Cube Aug 5, 2026
Company Deals

HighTide Therapeutics and SSY Group Ltd Join Forces to Tackle Metabolic and Aging Diseases

Fineline Cube Dec 20, 2024

China-based HighTide Therapeutics Inc. (HKG: 2511) has announced a strategic collaboration framework agreement with compatriot...

Company Drug

AIM Vaccine Co., Ltd Receives NMPA Clearance for Innovative Cell-Based Influenza Vaccine

Fineline Cube Dec 20, 2024

AIM Vaccine Co., Ltd (HKG: 6660), a China-based biopharmaceutical company, has announced that it has...

Company Deals

Henlius Biotech Expands Partnership with Palleon Pharmaceuticals for Autoimmune Disease Treatment

Fineline Cube Dec 20, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading biotechnology company based in China, has announced...

Company Drug

AIM Vaccine Co., Ltd Receives NMPA Approval for Second-Gen Tetanus Vaccine Clinical Trial

Fineline Cube Dec 20, 2024

China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced that it has received clinical trial...

Company Drug

MSD’s Clesrovimab for Infant RSV Protection: FDA Accepts BLA for Review

Fineline Cube Dec 19, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the U.S. Food and Drug...

Company Deals

Photys Therapeutics and Novo Nordisk Partner to Develop Proximity-Based Therapies for Cardiometabolic Diseases

Fineline Cube Dec 19, 2024

US-based Photys Therapeutics, Inc. has entered into an agreement with Denmark-based Novo Nordisk A/S (NYSE:...

Company Deals

Merck to Acquire HUB Organoids Holding B.V., Advancing Organoid Technology in Drug Development

Fineline Cube Dec 19, 2024

Merck (NYSE: MRK) has announced a definitive agreement with the intention to acquire HUB Organoids...

Company Deals

BioAge Labs and Novartis Partner to Discover Aging-Related Therapeutic Targets

Fineline Cube Dec 19, 2024

US-based BioAge Labs, Inc. has announced a strategic research partnership with Swiss pharmaceutical giant Novartis...

Company Medical Device

DaAn Gene Co., Ltd Receives NMPA Approval for Genetic Deafness Gene Detection Kit

Fineline Cube Dec 19, 2024

China-based DaAn Gene Co., Ltd, (SHE: 002030) affiliated with Sun Yat-sen University, has announced that...

Company Drug

MediLink Therapeutics’ YL201 Receives FDA Orphan Drug Designation for Small-Cell Lung Cancer

Fineline Cube Dec 19, 2024

Suzhou-based biotech company MediLink Therapeutics (Suzhou) Co., Ltd has announced that the US Food and...

Company Deals

BMS Regains Exclusive Rights to ABZ-706 in Greater China

Fineline Cube Dec 19, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has reached an agreement with China-based Ablaze Pharmaceuticals to regain...

Company Drug

Everest Medicines’ Nefecon Receives First Prescription for IgAN Treatment in Adults

Fineline Cube Dec 19, 2024

China-based Everest Medicines (HKG: 1952) has announced that its targeted-release budesonide, Nefecon, has been prescribed...

Company Drug

FDA Approves Xcovery Holdings’ Ensartinib for Untreated ALK-Positive NSCLC Patients

Fineline Cube Dec 19, 2024

On December 18, 2024, the Food and Drug Administration (FDA) granted approval for Betta Pharmaceutical...

Company Deals

INT Medical Instruments to Acquire Controlling Stake in Weiqiang Medical Technology for RMB 230 Million

Fineline Cube Dec 19, 2024

Shanghai INT Medical Instruments Co., Ltd. (HKG: 1501) has announced its intention to acquire at...

Company Drug

Janssen-Cilag Submits for IMBRUVICA Indication Extension in Untreated Mantle Cell Lymphoma

Fineline Cube Dec 19, 2024

Janssen-Cilag International NV has announced the submission seeking approval for an indication extension of IMBRUVICA...

Company Deals

iFlytek’s Subsidiary Xunfei Healthcare Technologies Lists on HKEX, Raises Over HKD 580 Million

Fineline Cube Dec 19, 2024

Xunfei Healthcare Technology Co., Ltd, a subsidiary of China-based information technology company iFlytek Co., Ltd...

Company Drug

Chengdu Kanghua Biological Receives NMPA Approval for Recombinant Norovirus Vaccine

Fineline Cube Dec 19, 2024

Chengdu Kanghua Biological Products Co., Ltd, (SHE: 300841), a leading biopharmaceutical company based in China,...

Company Medical Device

Sinocare Inc’s TRUE VIE CGMS Advances to 510(k) Substantive Review Stage at FDA

Fineline Cube Dec 19, 2024

Sinocare Inc (SHE: 300298), a China-based medical technology company, has announced that its continuous glucose...

Company Drug

Huadong Medicine’s HDM1005 Receives FDA Clearance for Heart Failure and Obesity Clinical Trial

Fineline Cube Dec 19, 2024

China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clearance from...

Company Drug

Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for SHR-1501 Combo in Bladder Cancer

Fineline Cube Dec 19, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading China-based pharmaceutical company, has announced that...

Posts pagination

1 … 280 281 282 … 704

Recent updates

  • Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership
  • Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline
  • Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication
  • Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance
  • Sino Biopharmaceutical’s BCL-2 Inhibitor TQB3909 Tablet Receives CDE Acceptance for CLL/SLL Treatment in Relapsed/Refractory Patients
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Company

Amgen Reports Q2 2026 Revenue of $10.05B, Driven by 26% Growth in Core Portfolio Despite Denosumab Decline

Company Drug

Allergan Aesthetics’ BOTOX Cosmetic sBLA Accepted by FDA for Masseter Muscle Prominence, Poised to Become First Neurotoxin Indication

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.